Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
doi: 10.1016/j.redox.2023.102650 64 MaXXiaoLLiuLYeLSuPBiEet al
N Engl J Med 369(8):722731 van der Graaf WT et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
The FDA requires this warning based on animal data, and notes that it is unknown whether these medications cause thyroid C-cell tumors, including medullary thyroid carcinoma, in humans
Microbiome 16S V1-V3 rRNA gene sequencing, alignment, and initial filtering were performed by BGI
For Research Use Only Not for human or veterinary consumption Not equivalent to any approved drug product Supplied by Nextday Peptides for controlled in-vitro laboratory research use only
The Phase I trial will study target dose levels of 5 mg/kg, 10 mg/kg and 20 mg/kg of PGN-EDODM1, with safety, transcript splicing and clinical outcome measures data from the 5 mg/kg cohort expected in 2024
US$ 28.02
US$ 22.60
US$ 21.12
US$ 26.65
US$ 28.99
